Bob, I agree with your assessment. One critical thing will be GSK's approach to efficacy news. If they want their shareholders to properly know what they have, we'll get a clear statement, otherwise it will be wordsmithed to keep investors guessing. I believe the efficacy milestone is for 50% tumor reduction, if that's clearly stated, we'll be off to the races.
The next few weeks could bring on a lot of news. IND acceptance, quarterly report, presentations at conferences, possibly another partnership, completion of the Single Dose Trial at any time, and the Efficacy Milestone.
IMGN is doing the right thing, they're completely on track wrt their business plan, and I believe the drug is working as well as they could have possibly hoped. As you said, with proof of efficacy the value of each partnership, news announcement, etc. will grow tremendously. It's just a matter of time, the efficacy milestone will either tell the tale, or it will be told by the Doctors at the appropriate conference.
Gary |
